307 research outputs found
An Antibody to De-N-Acetyl Sialic Acid Containing-Polysialic Acid Identifies an Intracellular Antigen and Induces Apoptosis in Human Cancer Cell Lines
Polysialic acid (PSA), an α2,8-linked homopolymer of N-acetylneuraminic acid (Neu5Ac), is developmentally regulated and its expression is thought to be restricted to a few tissues in adults. Recently, we showed that two human pathogens expressed a derivative of PSA containing de-N-acetyl sialic acid residues (NeuPSA). Here we show that an epitope identified by the anti-NeuPSA monoclonal antibody, SEAM 3 (SEAM 3-reactive antigen or S3RA), is expressed in human melanomas, and also intracellularly in a human melanoma cell line (SK-MEL-28), a human T cell leukemia cell line (Jurkat), and two neuroblastoma cell lines (CHP-134 and SH-SY5Y). SEAM 3 binding induced apoptosis in the four cell lines tested. The unusual intracellular distribution of S3RA was similar to that described for the PSA polysialyltransferases, STX and PST, which are also expressed in the four cell lines used here. Interestingly, suppression of PST mRNA expression by transfection of SK-MEL-28 cells with PST-specific short interfering RNA (siRNA) resulted in decreased SEAM 3 binding. The results suggest further studies of the utility of antibodies such as SEAM 3 as therapeutic agents for certain malignancies
Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations
The presence of a high number of macrophages within solid tumors is often significantly associated with poor prognosis and predict treatment failure for chemotherapy and radiotherapy. Macrophages are innate immune cells capable of performing diverse functions depending on the different signals from the microenvironment. The classically activated macrophage is commonly present during the early stages of tumor development while alternatively activated macrophages are associated with more advanced tumors. The distinction of the antitumoral macrophages from the pro-tumoral macrophages is not absolute. However, they have different cell surface markers such as mannose receptor (MRC1 or CD206) abundantly expressed by macrophages treated with interleukin-4 (IL-4). The important roles of macrophages in cancers suggest that it is important to develop novel therapies that target these cells. In the present study, we designed a probe using Polyamidoamine (PAMAM) fifth-generation (G5) dendrimers conjugated with mannose, Cyanine 7 (Cy7), and hydrazinonicotinamide (HYNIC) for target macrophages with high expression of MRC1 in the tumor. The intracellular uptake of 99mTc-HYNIC-dendrimer-mannose-Cy7 through the interaction with MRC1 in bone marrow-derived macrophages (BMDMs) untreated or treated with lipopolysaccharides (LPS) + interferon (IFN)Îł or IL-4 was analyzed. Our results show that high-density mannose dendrimers are preferentially bound by macrophages treated by IFNÎł and LPS that express lower levels of MRC1 than for macrophages treated by IL-4 that express high levels of MRC1. Furthermore, the intracellular 99mTc-HYNIC-dendrimer-mannose-Cy7 uptake in BMDMs was not inhibited in the presence of free mannose or glucose. This result suggests that 99mTc-HYNIC-dendrimer-mannose-Cy7 is not internalized via macrophage MRC1. Based on these findings, we concluded that MRC1 expression does not determine the uptake of high-density mannose dendrimers
Paradise revealed: first-class science rocked by the sound of the waves
Univ SĂŁo Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 SĂŁo Paulo, BrazilInst Nacl Ciencia & Tecnol, Inst Invest Imunol, SĂŁo Paulo, BrazilUniversidade Federal de SĂŁo Paulo, Dept Ciencias Biol, Diaderna, SP, BrazilFundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio de Janeiro, BrazilUniv SĂŁo Paulo, Fac Med, BR-05508900 SĂŁo Paulo, BrazilInst Nacl Canc, Div Biol Celular, Rio de Janeiro, BrazilUniversidade Federal de SĂŁo Paulo, Dept Ciencias Biol, Diaderna, SP, BrazilWeb of Scienc
Synthetic Elastography using B-mode Ultrasound through a Deep Fully-Convolutional Neural Network
Shear-wave elastography (SWE) permits local estimation of tissue elasticity,
an important imaging marker in biomedicine. This recently-developed, advanced
technique assesses the speed of a laterally-travelling shear wave after an
acoustic radiation force "push" to estimate local Young's moduli in an
operator-independent fashion. In this work, we show how synthetic SWE (sSWE)
images can be generated based on conventional B-mode imaging through deep
learning. Using side-by-side-view B-mode/SWE images collected in 50 patients
with prostate cancer, we show that sSWE images with a pixel-wise mean absolute
error of 4.5+/-0.96 kPa with regard to the original SWE can be generated.
Visualization of high-level feature levels through t-Distributed Stochastic
Neighbor Embedding reveals substantial overlap between data from two different
scanners. Qualitatively, we examined the use of the sSWE methodology for B-mode
images obtained with a scanner without SWE functionality. We also examined the
use of this type of network in elasticity imaging in the thyroid. Limitations
of the technique reside in the fact that networks have to be retrained for
different organs, and that the method requires standardization of the imaging
settings and procedure. Future research will be aimed at development of sSWE as
an elasticity-related tissue typing strategy that is solely based on B-mode
ultrasound acquisition, and the examination of its clinical utility.Comment: (c) 2020 IEEE. Personal use of this material is permitted. Permission
from IEEE must be obtained for all other uses, in any current or future
media, including reprinting/republishing this material for advertising or
promotional purposes, creating new collective works, for resale or
redistribution to servers or lists, or reuse of any copyrighted component of
this work in other work
Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders
IntroductionStandard medical therapy (SMT) in children with functional abdominal pain disorders (FAPD) includes cyproheptadine and amitriptyline. While percutaneous electrical nerve field stimulation (PENFS) has shown benefit, no study has compared outcomes of PENFS to SMT. We aimed to examine changes in abdominal pain, nausea and disability before and after treatment and compare outcomes between treatments.MethodsThe records of FAPD patients ages 11â21 years, treated with 4 weeks of PENFS, cyproheptadine or amitriptyline were reviewed. Outcomes were evaluated using validated questionnaires [Abdominal Pain Index (API), Nausea Severity Scale (NSS), and the Functional Disability Inventory (FDI)] at baseline and follow-up within 3 months (FU).ResultOf 101 patients, 48% received PENFS, 31% cyproheptadine and 21% received amitriptyline. Median ages were 17 (15â19), 16 (15â18) and 15 (11â16) years respectively and the majority were females (75%, 90% and 52% respectively). In the PENFS group, API (pâ=â0.001), NSS (pâ=â0.059) and FDI (pâ=â0.048) were significantly lower at FU. API (pâ=â0.034) but not NSS and FDI (pâ>â0.05) decreased significantly at FU in the amitriptyline group. API, NSS and FDI did not change significantly with cyproheptadine at FU (pâ>â0.05). FU API scores were lower in PENFS vs. cyproheptadine (pâ=â0.04) but not vs. amitriptyline (pâ=â0.64). The FDI scores were significantly lower in the amitriptyline vs. cyproheptadine group (pâ=â0.03).ConclusionTherapy with PENFS showed improvements in abdominal pain, nausea and disability while amitriptyline showed improvements in abdominal pain within 3 months of treatment. PENFS was more effective than cyproheptadine in improving abdominal pain. Amitriptyline improved disability scores more than cyproheptadine and showed promise for treatment. PENFS may be a good non-pharmacologic alternative for FAPD
A cadeia de valor de ostra nativa em Sergipe, Alagoas e Rio Grande do Norte.
Visando contribuir para o propĂłsito de promover o desenvolvimento sustentĂĄvel da aquicultura brasileira com foco na inovação, agregação de valor, ampliação de mercado e fortalecimento dos empreendimentos ou produtores rurais de pequeno porte e de base empresarial, o presente trabalho tem como objetivo realizar uma caracterização da cadeia de valor da ostra nativa (Crassostrea gasar) em Sergipe, Alagoas e Rio Grande do Norte.AquaciĂȘncia 2023
Lipoma of Guyonâs canal causing ulnar neuropathy
Lipoma is a benign soft tissue tumor which rarely causes neuropathy. In closed compartments such as Guyonâs canal, even small volume loss can lead to compression of nerve. Hence in such areas, even innocuous tumors such as lipomas can cause neuropathy and warrant surgery. We present one such case of ulnar neuropathy caused by lipoma of Guyonâs canal
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial
AbstractHematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T cellâreplete HLA-mismatched HSCT and may also benefit myeloablative conditioning (MAC) transplants. We conducted a phase II trial of short-course bortezomib plus standard tacrolimus/methotrexate after busulfan/fludarabine MAC in 34 patients with predominantly myeloid malignancies. Fourteen (41%) received 8/8 HLA-matched unrelated donor (MUD) and 20 (59%) received 7/8 HLA-mismatched related/unrelated donor peripheral blood stem cell grafts. Median age was 49 years (range, 21 to 60), and median follow-up was 25 months (range, 11 to 36). The regimen was well tolerated. No dose modifications were required. Neutrophil and platelet engraftment occurred at a median of 14 (range, 10 to 33) and 17 (range, 10 to 54) days, respectively. Median 30-day donor chimerism was 99% (range, 90 to 100), and 100-day grades II to IV and III to IV acute GVHD incidence was 32% and 12% respectively. One-year chronic GVHD incidence was 50%. Two-year cumulative incidence of both NRM and relapse was 16%. Two-year progression-free and overall survival rates were 70% and 71%, respectively. Outcomes were comparable to an 8/8 MUD MAC cohort (n = 45). Immune reconstitution was robust. Bortezomib-based MAC HSCT is well tolerated, with HLA-mismatched outcomes comparable with 8/8 MUD MAC HSCT, and is suitable for randomized evaluation. (clinicaltrials.gov: NCT01323920.
Type 2 diabetes seems not to be a risk factor for the carpal tunnel syndrome: a case control study
- âŠ